DP1 peptide
DP1 peptide is a high-affinity ROR1-binding peptide with a Kd value of 74.9 nM. When labeled with 68Ga, DP1 peptide serves as a PET imaging agent, which features rapid tumor uptake, favorable target-to-nontarget ratios in various tumor models, and renal clearance, enabling non-invasive quantitative visualization of ROR1 expression. DP1 peptide can be used in research related to melanoma, hepatocellular carcinoma, colorectal cancer, and non-small cell lung cancer.
For research use only. We do not sell to patients.
- Formula: C112H159N29O38
- Molecular Weight:2519.63
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Radionuclide-Drug Conjugates (RDCs) Isoforms
More
Biological Activity
|
RORα 74.9 nM (Ki) |
[68Ga]Ga-DP1 (3.125-400 nM; 1 h) binds to ROR1 in MC38 cells with high affinity, with a Kd value of 74.9 nM[1].
[68Ga]Ga-DP1) (10-60 min) shows significantly higher ROR1-specific uptake in MC38 cells than radiolabeled DP2 and DP3, with its uptake accounting for 7.26% of the total activity after 30 min of incubation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
[68Ga]Ga-DP1 (7.4 MBq; intravenous injection; single dose) achieves detectable tumor uptake in the A549 subcutaneous xenograft model, enabling visualization of ROR1 expression[1].
[68Ga]Ga-DP1 (7.4 MBq; intravenous injection; single dose) exhibits specific, measurable tumor uptake in the MC38 allograft model, with a favorable tumor-to-muscle ratio at 60 min post-injection. Moreover, excess PR7 blocks its uptake, confirming the specificity for ROR1[1].
[68Ga]Ga-DP1 (7.4 MBq; intravenous injection; single dose) achieves detectable specific tumor uptake in the B16F10 allograft model, with uptake levels lower than those in the MC38 model, which is consistent with the lower expression level of ROR1 in B16F10 tumors[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (male, 6-8 weeks old, subcutaneous xenograft model)[1]
-
Dosage:7.4 MBq
-
Administration:i.v.; single dose
-
Result:Reached tumor uptake of 0.52% ID/g at 30 min postinjection.
Showed tumor-to-muscle, tumor-to-kidney, and tumor-to-heart ratios at 30 min postinjection.
-
Animal Model:BALB/c nude (male, 6-8 weeks old, subcutaneous xenograft model)[1]
-
Dosage:7.4 MBq
-
Administration:i.v.; single dose
-
Result:Reached tumor uptake of 0.50% ID/g at 30 min postinjection.
Showed tumor-to-muscle, tumor-to-kidney, and tumor-to-heart ratios at 30 min postinjection.
-
Animal Model:C57BL/6 (male, 6-8 weeks old, subcutaneous allograft model)[1]
-
Dosage:7.4 MBq; 100 μg PR7 (blocking dose)
-
Administration:i.v.; single dose; i.v.; single coinjection (blocking dose)
-
Result:Reached tumor uptake of 0.65% ID/g at 30 min postinjection and 0.94% ID/g at 60 min postinjection.
Showed significantly reduced tumor uptake (P < 0.001) in the PR7 blocking group.
Reached kidney accumulation of 27.90% ID/g at 30 min postinjection and 20.91% ID/g at 60 min postinjection.
Achieved a tumor-to-muscle ratio of 2.47 at 60 min postinjection.
-
Animal Model:C57BL/6 (male, 6-8 weeks old, subcutaneous allograft model)[1]
-
Dosage:7.4 MBq; 100 μg PR7 (blocking dose)
-
Administration:i.v.; single dose; i.v.; single coinjection (blocking dose)
-
Result:Reached tumor uptake of 0.40% ID/g at 30 min postinjection, which was significantly lower than uptake in MC38 tumors.
Showed significantly reduced tumor uptake in the PR7 blocking group.
Showed tumor-to-muscle, tumor-to-kidney, and tumor-to-heart ratios at 30 min postinjection.
Chemical Information
-
Molecular Weight 2519.63
-
Formula C112H159N29O38
-
Sequence
Tetraxetan-Ser-Asp-Ile-Asn-Asp-Arg-Gln-Ile-Pro-Gly-Tyr-Ser-Thr-Tyr-Trp-Gly-Asp-Phe-NH2
-
Sequence Shortening
Tetraxetan-SDINDRQIPGYSTYWGDF-NH2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
DP1 peptide Related Classifications
HY-P11858 Related Classifications
Powered by Bioz